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Background: Long term use of antiretroviral therapy (ART) in persons living with human immunodeficiency virus
(PLWHIV) is associated with disturbances in blood lipids which should be monitored. More data on such
disturbances are needed in Cameroon to persuade the country program to institute their routine monitoring. We
then sought to determine the prevalence and timing of dyslipidaemia in PLWHIV and receiving ART in a
predominantly rural Cameroonian setting.
Methods: A cross-sectional study conducted between August and October 2012 in HIV-infected persons aged
15 years or more and receiving first-line ART for at least six months at The Nkongsamba Regional Hospital in
Cameroon. Lipid assays were carried out by enzymatic-linked colorimetric methods. A multiple logistic regression
model was used to assess for factors related to dyslipidaemia.
Results: Included were 114 participants of whom 83 (72.8%) were females. Their median age was 43 years (IQR: 36–51)
and their median CD4 count was 436 cells/μl (IQR: 275–585) after a median duration on ART of 36 months (IQR: 12–60).
The prevalence of dyslipidaemia was 70.2%. Hypercholesterolaemia was observed in 34 (29.8%) patients. One-third of
them had a high LDL-cholesterol level (LDL-c≥ 130 mg/dl). Hypertriglyceridaemia (TG≥ 150 mg/dl) was present in 59
(51.8%) cases. The proportion of patients with a low HDL-cholesterol (HDL-c < 40 mg/dl) was 18.4% while those with a
ratio of TC/HDL-c≥ 5 were about 16.7%. A duration of 2–4 years on ART (adjusted Odd Ratio, aOR = 5.22, 95% CI:
1.43-19.06, p = 0.01), current smokers (aOR = 15.94, 95% CI: 1.13-225.61, p = 0.04) and a concurrent metabolic disease
(aOR = 12.54, 95% CI: 1.02-153.86, p = 0.48) were independently associated with pro-atherogenic LDL-c values. Alcohol
users had a more friendly LDL-c profile (aOR = 0.24, 95% CI: 0.07-0.74, p = 0.01).
Conclusion: The study has demonstrated a high prevalence of dyslipidaemia in HIV-patients receiving first-line ART in a
predominantly rural setting of Cameroon. There is a need for the country HIV program to institute laboratory monitoring
of blood lipids in patients over two years on first line ART with a focus on smokers.
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At the end of 2012, an estimated 35.3 million people were
living with human immunodeficiency virus (HIV) world-
wide [1]. Sub-Saharan Africa, a region with only 12% of the
global population remains the region most heavily affected
by HIV accounting for about 70% of the global burden of
HIV. The scaling up of antiretroviral therapy (ART) in low-* Correspondence: cavinep@yahoo.co.uk
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reproduction in any medium, provided the orand middle-income countries has transformed national
AIDS (acquired immune deficiency syndrome) responses
and generated broad-based health gains. Globally, from
1996 to 2012, a total of 6.6 million AIDS-related deaths
have been averted, including 5.5 million deaths in low- and
middle-income countries due to increased access to anti-
retroviral therapy (ART) [1]. However, long-term use of
ART is related to metabolic (dyslipidaemia, insulin resist-
ance, and diabetes) and cardiovascular complications [2,3].
Antiretroviral therapy can induce raised levels of total chol-
esterol (TC), low density lipoprotein-cholesterol (LDL-c)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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lipoprotein-cholesterol (HDL-c) levels [4]. In a large cross-
sectional study, the prevalence of hypercholesterolemia
(>6.2 mmol/L), hypertriglyceridemia (>2.3 mmol/L), and
low HDL-cholesterol (<0.9 mmol/L) was 10 to 27 per cent,
23 to 40 per cent, and 19 to 27 per cent, respectively, de-
pending on the antiretroviral regimen [5]. The treatment
options available for the management of dyslipidaemia in
HIV-infection are similar to those in the general population
with an additional option of switching to a different anti-
retroviral class with a friendlier lipid profile [3].
Cameroon with an estimated population of 19.4 mil-
lion in 2010 [6] had an HIV prevalence rate in 2011 of
4.3% down from 5.5% in 2004 [7]. The ART coverage in-
creased from 36.5% in 2010 to 49.6% in 2011 [8]. HIV
infection in ART-naïve Cameroonians has been shown
to be associated with dyslipidaemia characterised by a
significant decrease in total oxidant ability (TAA), LDL-
c, HDL-c and TC; and increased malondialdehyde
(MAA) and lipid peroxidation indices (LPI) than in their
seronegative counterparts [9-12]. Routine monitoring of
serum lipids in patients on ART is not a common prac-
tice in the country. In 2011, however, following recom-
mendations from WHO 2010 guidelines, stavudine
(D4T) was phased out due to its metabolic toxicity
amongst others [13]. One study in the country on ART-
associated dyslipidaemia, had found that ART com-
pounded the effects of HIV by increasing lipid oxidation
[9] while another demonstrated that patients on first-
line ART had high levels of total cholesterol, LDL-c and
high TC/HDL-c ratio compared with ART-naive patients
[14]. These studies were carried out in the urban setting
and recommended that lipid profile and other cardiovas-
cular risk factors should be monitored in patients on
ART so that any untoward effects of treatments can be
optimally managed. Their recommendations are yet to
be applied in full.
A small study carried out in the Littoral Region of
Cameroon, reported higher levels of TC, TG and LDL-c
with lower levels of HDL-c in the urban than in the rural
area. These rural–urban differences in lipid profile were at-
tributed to differences in dietary habits. The traditional di-
ets of rural populations are rich in many vegetables and
season fruits that enhance hepatic cholesterol clearance
allowing for a less atherogenic lipid profile in the rural
population [15].
However, data on dyslipidaemia among HIV-infected pa-
tients using ART in a rural setting are virtually non-
existent. We carried out an opportunistic cross sectional
study to determine the prevalence of dyslipidaemia in rural
Cameroon using in service data from an HIV clinic wherein
all patients have an unknown lipid profile. We hoped that
the findings of this study would inform health workers at




The study was conducted at the Regional Hospital of
Nkongsamba in the Moungo Division of the Littoral
Region of Cameroon. It is a second level of reference
public health facility with a catchment area of over
321,295 inhabitants [6] most of whom are rural peasant
farmers. Users of the clinic come from the city of
Nkongsamba obviously but massively constitute of refer-
rals from the rural municipalities of Melong, Bare-
Bakem, Nlonako, Manjo, Loum, Njombe-Penja, Mbanga,
Bonalea and Dibombari that make up the Moungo Div-
ision; equally from neighbouring rural areas of Bangem
and Tombel in the South-West Region and from the
rural municipalities of Kekem and Santchou in the West
Region of Cameroon. The clinic was established in 2005
and offers voluntary HIV counselling and testing (VCT),
ART and limited community outreach services to pa-
tients on ART.
Ethical aspects
Ethical approval was obtained from the Centre for Medical
Laboratory Technicians in Yaounde, Cameroon (Centre
d’Enseignement Spécialisé des Techniques d’Analyses Méd-
icales de Yaounde). Site permission to conduct the study
was provided by The Director of The Nkongsamba Re-
gional Hospital. A written informed consent from each of
the participants or legal representatives was duly obtained.
Participants and study design
We carried out a cross sectional study involving HIV-
infected patients of age 15 years and above receiving
ART and returning for their six-monthly laboratory
check-up between August 2012 and October 2012. The
study was opportunistic with a sampling method of con-
venience in the sense that, we took advantage of patients
turning up voluntarily for their routine and subsidised
semester laboratory monitoring tests to which we added
the lipid measuring tests according to our constraint
budget. Lipid profile had never been included in the sub-
sidised laboratory kit nor had been part of a routine
measurement in this centre. Prior to sample collection,
sociodemographic, clinical, laboratory and treatment re-
lated variables of interest were collected by interviews
and from medical records using a structured question-
naire. Blood samples were collected in the mornings
after an overnight fasting and centrifuged at 3000 g per
minute for 30 minutes. The serum obtained was stored at
4°C and later used for lipid assays using a spectrophotom-
eter (Helios Gamma, UVG 123019, Thermo Electron Cor-
poration, England) according to the kit material referenced
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TC concentration was determined using colorimetric en-
zymatic techniques based on the successive action of chol-
esterol oxidase and peroxidase; HDL-c concentration in the
serum supernatant was determined by the same process
after the precipitation of very low density lipoprotein
(VLDL) cholesterol, LDL-c and chylomicrons. Results were
calculated using the formula: TC (g/l) or HDL-c (mg/dl)
concentrations = (Optical Density at 500nm of sample ÷
Optical Density at 500nm of standard) × Concentration of
standard (essentially as recommended by the manufacturer
in the kits with all units later converted to mg/dl were ne-
cessary). LDL-c concentration was determined using the
formula of Friedewald et al. [16]: LDL-c (mg/dl) = TC
(mg/dl)-[HDL-c (mg/dl)-Triglycerides (mg/dl)/5].
Data analysis
Data analyses were performed using Stata® 12.1(StataCorp
LP, TX77845, USA). The data set was checked for logical
inconsistencies, illegal codes, omissions and improbabilities
by tabulating, summarising, describing and plotting vari-
ables. Missing observations were excluded where they con-
stituted a small random proportion but were included if
they were found to be differential amongst subgroups.
Our outcomes of interest included the lipid parameters:
TC, HDL-c, LDL-c, TG and TC/HDL-c ratio. In accordance
with the United States National Cholesterol Education Pro-
gram, Adult Treatment Panel III (NCEP-ATP III) guide-
lines, abnormal lipid profile was defined as TC ≥ 200 mg/dl,
HDL-c < 40 mg/dl, LDL-c ≥ 130 mg/dl, TG ≥ 150 mg/dl and
TC/HDL-c ratio ≥ 5 [17]. Putative risk factors for dyslipidae-
mia included: age, sex, CD4 count, ART regimen, duration
of and adherence to ART, smoking, alcohol use, presence of
metabolic and/or cardiovascular disease. No factor was con-
sidered as an a priori confounder or effect modifier.
Summary statistics were presented as proportions for cat-
egorical variables and as means (standard deviations) or
medians (IQR: Inter-quartile Range) for continuous vari-
ables. Pearson Chi-square analyses were used to examine
the difference in proportion of abnormal lipid parameters
between the various categories of an explanatory variable.
A multivariable logistic regression model was set up to
screen for factors independently associated with a pro-
atherogenic lipid profile. Adjusted odd ratios (aOR) and
their 95% confidence intervals (95%CI) obtained. The P-
values for hypotheses testing were calculated from Wald or
likelihood ratio tests (LRT).
Results
Participants
The study included patients receiving ART and returning
to the clinic between August 2012 and October 2012 for
their routine biannual laboratory monitoring. A total of 200patients were recruited of which 86 were children below
15 years old who were excluded from the study.
The results of the 114 adults are reported. Of these, 83
(72.8%) were females (Table 1). Their median age was
43 years (IQR: 36–51) and their median CD4 count was
436 cells/μl (IQR: 275–585) after a median duration on
ART of 36 months (IQR: 12–60). With lamivudine
(3TC) constantly present in all the first line triple-
combination antiretroviral regimens, zidovudine (AZT)
completed the nucleotide reverse transcriptase inhibitor
(NRTI) backbone in 75 (65.8%) cases while nevirapine
(NVP) in 60 (52.6%) patients was the preferred non-
nucleotide reverse transcriptase inhibitor (NNRTI) op-
tion. Up to 49 (43.6%) patients reported using alcohol,
but only six could declare that they were current
smokers. Metabolic and cardiovascular diseases in 16
subjects were rare conditions amongst the participants
(< 10%). Ten of them (9%) reported being on a diet
while only five (4.5%) had declared ever interrupted their
antiretroviral treatment.Lipid profile of participants
Figures 1 shows that, the median serum concentration of
total cholesterol was 187 mg/dl (IQR: 166–201) with a
prevalence of hypercholesterolaemia of 29.8% (Figure 2).
One-third of the patients had a high LDL-c and the median
serum LDL-c concentration was 118 mg/dl (IQR; 95–139).
Hypertryglyceridaemia was present in 59 (51.8%) cases and
the median triglyceride level was 152 mg/dl (IQR: 97–183).
The proportion of patients with a low HDL-c was 18.4%
and that with a high ratio of TC/HDL-c was 16.7%. The
number of patients with an abnormal lipid level was 80
(70.2%).Factors associated with poor lipid profiles
In multivariable logistic regression analysis (Table 2), there
was some evidence that being on ART for two to four years
was associated with a higher LDL-c level (aOR = 5.22,
95% CI: 1.43-19.06, p = 0.01) but above four years on ART,
the evidence was very weak (aOR= 1.59, 95% CI: 0.45-5.57,
p = 0.4). While stavudine and tenofovir (TDF) appeared to
be associated with a poorer lipid profile than zidovudine,
efavirenz was likely to have a friendlier lipid profile than ne-
virapine. Smoking was linked to very high levels of LDL-c
(aOR = 15.94 95% CI: 1.13-225.61, p = 0.04) as well as very
high levels of TC and TG. Meanwhile alcohol consumption
was associated with low LDL-c level (aOR = 0.24, 95% CI:
0.07-0.74, p = 0.01) as well as lower levels of TC, TG and
higher levels of HDL-c. Patients with existing metabolic
conditions were associated with very high levels of LDL-c
(aOR = 12.54, 95% CI: 1.02-153.86, p = 0.048) and higher
levels of TC, TG but with higher levels of HDL-c. Being
male, young or having a CD4 count < 350 cells/μl was
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*ART = antiretroviral therapy, **NRTI = nucleotide reverse transcriptase inhibitors, ***
NNRTI = non-nucleotide reverse transcriptase inhibitor, AZT = zidovudine, 3TC =
lamivudine, TDF = tenofovir, D4T = stavudine, EFV = efavirenz, NVP = nevirapine.
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was little or no evidence to support these relationships.Discussion
The study has demonstrated a high prevalence of dysli-
pidaemia (70.2%) in HIV-patients receiving first-line
ART in a predominantly rural population of Cameroon.
Hypertriglyceridaemia (51.8%), raised levels of LDL-c
(33.3%) and hypercholesterolaemia (29.8%) were the
most common forms of dyslipidaemia. The duration on
ART, smoking, alcohol use and the presence of a con-
current metabolic disease were significantly associated
with high LDL-c values. LDL-cholesterol is a pro-
atherogenic marker.
Though high, the prevalence of dyslipidaemia in our
setting is lower to the reported rate of 82.3% in patients
using ART in an urban population of Southern Ethiopia
[18] and to that observed in Dar es Salaam, Tanzania
where the prevalence was 76% in ART-naive patients
[19] but much more higher than prevalence rates ob-
served in the developed world [5]. The prevalence rates
of hypertriglyceridaemia and high LDL-c levels in our
study were comparable to those observed in Southern
Ethiopian study (55.8% and 33.6% respectively) [18] but
were respectively higher (43.5%) and lower (46.4%) in
the urban Cameroon setting [14]. The prevalence rates
of hypercholesterolaemia and low HDL-c concentration
in our study were lower than those reported in these
studies. In the general population of Cameroon, dyslipi-
daemia was observed to be more prevalent in the urban
than in the rural setting [15]. It is however difficult to
ascertain whether the prevalence and pattern of dyslipi-
daemia in HIV-infected population in rural area is differ-
ent from that in an urban settings because dyslipidaemia
in HIV-infected individuals is a complex condition, with
multiple contributing factors including the HIV virus it-
self, individual genetic characteristics and antiretroviral



























Figure 1 Lipid profile of the study population.
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http://www.biomedcentral.com/1471-2458/14/236Women were associated with a greater risk of lipid dis-
turbances than men though our study lacked the evidence
to support this association. Increasing the power of our
study and adjusting for body mass index could have im-
proved our probability of detecting the sex difference. How-
ever, this finding is coherent with current knowledge that
women experience more ART-induced (metabolic) adverse
effects than men [21].
As age increases, pro-atherogenic lipid parameters also
increase [19]. In our study, though it appeared that younger
persons below the age of 25 years were at lower risk of dys-
lipidaemia, there was no pattern for the association be-
tween age and abnormal lipid profile. Poor categorisation
of age groups in our study might have been responsible for





































Figure 2 Prevalence of dyslipidaemia in HIV-infected patients receivinSevere immune suppression (low CD4 count) has been
associated with dyslipidaemia in ART-naive HIV infected
persons [19,22,23]. However, in a cohort of persons doing
well on highly active antiretroviral therapy (HAART) with a
sufficiently improved mean CD4 count, there is little vari-
ability in CD4 count of the group and therefore a difference
in dyslipidaemia cannot be attributed to differences in CD4
counts. The latter is the case in our study and in other
studies involving patients on HAART [14,18].
HAART is associated with a cardio-protective lipid profile
in the short term [24] because after initiation of ART, lipid
levels return to baseline levels but soon they rise above pre-
sero-conversion levels in the long term [25]. In our cohort,
patients with duration on ART above two years were signifi-













Table 2 Factors associated with dyslipidaemia from a multiple logistic regression model
Variables TC ≥ 200 mg/dl LDL-c ≥ 130 mg/dl TG ≥ 150 mg/dl HDL-c < 40 mg/dl TC/HDL-c ratio ≥5
Adjusted OR (95%CI) Adjusted OR (95%CI) Adjusted OR (95%CI) Adjusted OR (95%CI) Adjusted OR (95%CI)
Sex
Male 1 1 1 1 1
Female 2.11 (0.64-6.95) 0.44 (0.14-1.38) 1.47 (0.53-4.08) 2.55 (0.51-12.64) 3.25 (0.56-18.92)
P-value 0.22 0.16 0.45 0.25 0.19
Age group (years)
15 – 24 1 1 1 1 1
25 – 34 0.91 (0.19-4.28) 1.00 (0.03-31.54) 1.20 (0.27-5.30) 1.47 (0.21-10.40) 1.42 (0.19-10.76)
35+ NA 0.28 (0.01-11.70) NA NA NA
P-value 0.56 0.07 0.81 0.70 0.48
CD4 count
<350 1 1 1 1 1
350 – 499 1.12 (0.30-4.14) 1.30 (0.38-4.48) 1.23 (0.38-3.89) 1.24 (0.27-5.66) 1.23 (0.33-8.33)
500+ 2.45 (0.73-8.26) 0.77 (0.22-2.64) 0.97 (0.33-2.86) 0.57 (0.11-2.76) 1.28 (0.25-6.59)
P-value 0.56 0.07 0.46 0.65 0.48
Time on ART(years)
<2 1 1 1 1 1
2 – 4 2.16 (0.64-7.33) 5.22 (1.43-19.06) 0.51 (0.16-1.59) 1.71 (0.34-8.48) 1.65 (0.33-8.33)
5+ 1.11 (0.33-3.75) 1.59 (0.45-5.57) 0.66 (0.22-1.91) 2.49 (0.49-12.51) 1.67 (0.30-9.20)
P-value 0.56 0.07 0.46 0.65 0.48
NRTI regimen
AZT-based 1 1 1 1 1
D4T-based 2.17 (0.22-21.47) 1.47 (0.08-25.46) 5.29 (0.44-64.26) 5.62 (0.33-95.76) 6.79 (0.40-116.57)
TDF-based 1.89 (0.62-5.80) 1.25 (0.38-4.06) 2.28 (0.79-6.63) 0.74 (0.17-3.26) 1.37 (0.31-6.03)
P-value 0.56 0.07 0.46 0.65 0.48
NNRTI regimen
EFV-based 1 1 1 1 1
NVP-based 1.27 (0.42-3.81) 1.20 (0.38-3.76) 0.80 (0.29-2.24) 3.96 (0.85-18.52) 4.09 (0.85-19.73)
P-value 0.67 0.76 0.67 0.08 0.08
Smoking
No 1 1 1 NA NA
Yes 5.84 (0.51-67.18) 15.94 (1.13-225.61) 6.06 (0.44-83.99) NA NA
P-value 0.16 0.04 0.18
Alcohol intake
No 1 1 1 1 1
Yes 0.50 (0.18-1.41) 0.24 (0.07-0.74) 0.99 (0.40-2.47) 0.70 (0.21-2.42) 0.58 (0.15-2.17)
P-value 0.19 0.01 0.99 0.58 0.42
Heart condition
No 1 NA 1 NA NA
Yes 0.47 (0.04-6.15) NA 0.25 (0.02-3.24) NA NA
P-value 0.56 0.29
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Table 2 Factors associated with dyslipidaemia from a multiple logistic regression model (Continued)
Metabolic condition
No 1 1 1 1 1
Yes 1.42 (0.21-9.79) 12.54 (1.02-153.86) 2.97 (0.38-22.94) 0.67 (0.06-8.08) 1.02 (0.07-14.69)
P-value 0.72 0.048 0.30 0.75 0.99
Special diet
No 1 1 1 1 1
Yes 3.36 (0.56-20.20) 4.19 (0.42-42.07) 1.81 (0.28-11.69) 3.95 (0.45-34.50) 1.06 (0.08-14.17)
P-value 0.19 0.22 0.53 0.22 0.97
ART interruption
No 1 1 1 NA NA
Yes 0.75 (0.05-11.45) 0.89 (0.03-26.83) 7.37 (0.36-149.65) NA NA
P-value 0.84 0.95 0.19
*ART = antiretroviral therapy, **NRTI = nucleotide reverse transcriptase inhibitors, ***NNRTI = non-nucleotide reverse transcriptase inhibitor, AZT = zidovudine,
3TC = lamivudine, TDF = tenofovir, D4T = stavudine, EFV = efavirenz, NVP = nevirapine, NA = not applicable.
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profile should be instituted after two years on first line ART
in Cameroon. Current guidelines of The National AIDS
Control Committee of Cameroon do not allow for routine
monitoring of lipid parameters for patients receiving first
line ART [26]. Though an earlier study in Cameroon by
Yone et al. did recommend monitoring of lipid profile in pa-
tients on first line ART, the timing for this laboratory assess-
ment was not mentioned.
Stavudine is known to be associated with a significant
increase in lipid parameters compared with either zi-
dovudine [27,28] or tenofovir [29]. Our data suggested a
similar comparison. Following the 2010 WHO Guide-
lines [13], most patients on stavudine had already been
switched to either zidovudine or tenofovir at the time of
the study. The effect of this intra- class switching has
not been accounted for but the likely impact on the odd
ratios would be a bias towards unity because the switch-
ing was independent of this study.
A head-to-head comparison of efavirenz with nevirapine
in initial regimens demonstrated a more favourable lipid
profile for nevirapine at 48 weeks [30]. Our data showed the
contrary and the likely explanation is that, in our cohort,
regimens were selectively prescribed to certain groups of pa-
tients according to their immune status or the presence of
tuberculosis or pregnancy. This selection bias could account
for the difference observed.
A comprehensive meta-analysis by Craig et al. has dem-
onstrated that compared with non-smokers, cigarettes
smokers had poorer lipid profiles both in the general popu-
lation [31] and even amongst the HIV-positive population
[32]. Though the proportion of current smokers in our
sample population was very small and made up exclusively
of men, the association is in agreement with current know-
ledge and in this study smokers even had the highest odds
of dyslipidaemia than any other subgroup. Information biasassociated with under-reporting of undesirable lifestyles is
likely to be the case here but such a big odd ratio is also un-
likely to be a chance finding. Smoking cessation would thus
be strongly recommended.
The proportion of alcohol users in our study sample
was high just like in the general Cameroon population.
Our data suggest that alcohol consumers have better
lipid profiles than non-drinkers. It is however not known
what unit of daily intake was associated with a
favourable lipid profile because we could not determine
the quantity consumed per participant. With women in
a rural African setting making up the majority of our
study population, it is plausible that users of alcohol
would be mostly low-to-moderate drinkers. Alcohol con-
sumption should however be discouraged because its
deleterious effects on ART adherence and HIV progres-
sion [33] and on other cardiac-metabolic disorders [34]
do outweigh this supposedly positive effect on lipid pa-
rameters. Incidentally, patients with existing metabolic
disorders (all of whom were sufferers of type 2 diabetes
mellitus) have been shown to have very high odds of
dyslipidaemia (LDL-c) in this study.
Our study had a couple of draw-backs that may impact
on its quality. The sample size was small so much so
that the precision of our odd ratios was low and we
lacked the power to detect significant differences we
hoped to. Its opportunistic nature had somehow intro-
duced selection bias because patients turning up for
their routine check-up might be different from those
defaulting. The cross-sectional design made it impossible
to assume any causality.Conclusion
In conclusion, dyslipidaemia is highly prevalent in patients
receiving HAART but with no peculiarities in rural
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proved making HIV a chronic manageable disease, there is
a need for the country HIV program to institute laboratory
monitoring of lipids for patients in their third year on first
line ART with a special attention to be focused on smokers.
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